Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2022

Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure

Job Verdonschot
Pierpaolo Pellicori
Franco Cosmi
  • Fonction : Auteur
Mark Hazebroek

Résumé

Background: Left ventricular ejection fraction (LVEF) can provide hemodynamic information and may influence the response to spironolactone and other heart failure (HF) therapies. Aims: To study the patient characteristics and circulating protein associations with LVEF, and whether LVEF influenced the response to spironolactone. Methods: HOMAGE enrolled patients aged >60 years at high risk of developing HF with a LVEF ≥45%. 527 patients were randomized to either spironolactone or standard-of-care for ≈9 months. 276 circulating proteins were measured using Olink® technology. Results: 364 patients had available LVEF determined by the Simpson's bi-plane method. The respective LVEF tertiles were: Tertile1:<60% (N = 122), Tertile2:60%-65% (N = 121), and Tertile3:>65% (N = 121). Patients with a LVEF>65% had smaller LV chamber size and volumes, and lower natriuretic peptide levels. Compared to patients with a LVEF<60%, those with LVEF>65% had higher levels of circulating c-c motif chemokine ligand-23 and interleukin-8, and lower levels of tissue plasminogen activator, BNP, S100 calcium binding protein A12, and collagen type I alpha 1 chain (COL1A1). Spironolactone significantly reduced the circulating levels of BNP and COL1A1 without significant treatment-by-LVEF heterogeneity: BNP change β = -0.36 Log2 and COL1A1 change β = -0.16 Log2 (P < 0.0001 for both; interactionP>0.1 for both). Spironolactone increased LVEF from baseline to month 9 by 1.1%, P = 0.007. Conclusion: Patients with higher LVEF had higher circulating levels of chemokines and inflammatory markers and lower levels of stretch, injury, and fibrosis markers. Spironolactone reduced the circulating levels of natriuretic peptides and type 1 collagen, and increased LVEF. This article is protected by copyright. All rights reserved.
Fichier principal
Vignette du fichier
HOMAGE_LVEF.pdf (494.83 Ko) Télécharger le fichier
HOMAGE_LVEF_Supplement.docx (119.62 Ko) Télécharger le fichier
HOMAGE_LVEF_Supplement.pdf (832.72 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03588878 , version 1 (25-02-2022)

Identifiants

Citer

João Pedro Ferreira, Job Verdonschot, Nicolas Girerd, Erwan Bozec, Pierpaolo Pellicori, et al.. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, ⟨10.1002/ejhf.2455⟩. ⟨hal-03588878⟩
122 Consultations
128 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More